MétaCan
Menu
Back to cohort
Record W4377246471 · doi:10.1093/jsxmed/qdad060.397

(423) A Case Series of Successful Off-label Use of Flibanserin

2023· article· en· W4377246471 on OpenAlexaff
Philip Trowbridge, Mukul Padhye, Rachel Rubin

Bibliographic record

VenueThe Journal of Sexual Medicine · 2023
Typearticle
Languageen
FieldMedicine
TopicSexual function and dysfunction studies
Canadian institutionsGeorgetown Hospital
Fundersnot available
KeywordsHypoactive sexual desire disorderOrgasmLibidoSexual dysfunctionPsychologySexual desireDiscontinuationMedicinePsychiatryInternal medicineHuman sexuality

Abstract

fetched live from OpenAlex

Abstract Introduction Flibanserin was the first FDA approved drug for hypoactive sexual desire disorder (HSDD) in premenopausal women, but was initially studied as an antidepressant without concern for age or gender. Flibanserin acts as partial agonist at the serotonin receptor 1A and antagonist at serotonin 2A receptor. The mechanism of action is thought to be due to an increase in dopamine and norepinephrine. Post hoc analysis during the pivotal trials showed improvement not just in desire, but in all domains of the Female Sexual Function Index (FSFI) including orgasm, arousal, lubrication and satisfaction. Off label use of flibanserin therefore is of interest to sexual medicine providers. Objective Described here, are four off label uses for flibanserin with successful outcomes in patient’s symptoms and quality of life, including post-orgasmic illness syndrome (POIS), low libido in a eugonadal male, a postmenopausal female with HSDD, and a patient with post-finasteride syndrome (PFS). Methods The first case is of a 40-year-old male patient who presented with a 10 year history of acquired POIS, with significantly debilitating symptoms lasting 1 week after orgasm. After trying a number of different multimodal treatment approaches he finally was on a regimen of Bupropion, Lexapro, Silodosin, Ritalin and Tramadol with a reduction in the duration of his symptoms from 1 week to 4 days, without a change in symptom intensity. Patient was then trialed on 200mg gabapentin nightly and 100mg flibanserin nightly, with progressive discontinuation of prior medications. The second patient, is a 77-year-old hypersexual, postmenopausal woman with a significant trauma history, who presented with gradually worsening HSDD despite adequate lubrication on estring, who was started on 100mg flibanserin nightly. Patient 3 is a 51-year-old male who presented with a 1 year history of low libido and mild erectile dysfunction despite normal testosterone levels and minimal improvements with sildenafil, who was trialed on 100mg flibanserin nightly. The fourth case involves a 26-year-old male presenting with PFS symptoms of erectile dysfunction, decreased libido, genital shrinkage, testicular pain, anxiety and brain fog. Patient had some improvement of erections post discontinuation of finasteride, but was only able to achieve full erection with use of tadalafil. Patient was trialed on 2 months of 100mg flibanserin. Results All four of these patients experienced significant improvement in their presenting symptoms after starting flibanserin nightly. Patient 1, with POIS, had markedly reduced symptom intensity and reduced duration of POIS from 7 days to 1 day. Patient 2 and 3 regained prior libido and quality of life within 2-3 months. Lastly, patient 4 experienced marked improvement in sleep, brain fog, libido and erectile function. Conclusions These cases indicate that flibanserin may be useful to more than premenopausal women and should be studied as a medication with additional pro-sexual affects like bupropion and buspar. Disclosure No

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.578
Threshold uncertainty score0.354

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.131
GPT teacher head0.345
Teacher spread0.214 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueThe Journal of Sexual MedicineSame topicSexual function and dysfunction studiesFrench-language works237,207